Navigation Links
Express Scripts Announces Record Third Quarter Earnings and 2011 Guidance
Date:10/27/2010

10-Benefit related to client contract amendment (2)

--(0.03)-Transaction-related costs (3)

-0.02-0.03Benefit related to insurance recovery  (4)

---(0.02)Termination of bridge financing (5)

---0.07Legal settlement (6)

-0.04-0.04Amortization of: Legacy intangible assets (7)

0.010.010.030.03NextRx-related intangible assets (8)

0.04-0.10-EPS from continuing operations, adjusted$  0.65$ 0.42$  1.80$ 1.30EPS from discontinued operations, as reported$ (0.01)$
-$ (0.04)$
-Non-recurring items: Impairment and other charges (9)

0.01-0.04-EPS from discontinued operations, adjusted$
-$
-$
-$
-Total EPS, adjusted$  0.65$  -$ 0.42$  1.79$ 1.30 The Company is providing diluted earnings per share excluding the impact of non-recurring charges and intangibles amortization in order to compare the underlying financial performance to prior periods. (1)Integration-related costs include those costs directly related to the acquisition of NextRx, primarily comprised of transition services, integration, site closures and severance costs of $15.1 million ($9.5 million net of tax) and $62.7 million ($39.5 million net of tax) included in cost of revenues for the three and nine months ended September 30, 2010, respectively.
Additionally, the Company incurred integration-related costs of $12.3 million ($7.7 million net of tax) and $22.7 million ($14.3 million net of tax) included in selling, general and administrative expense in the three and nine months ended September 30, 2010, respectively. (2) Non-recurring benefit relating to an amendment of a client contract of $30.0 million ($18.9 million net of tax) is included as an increase to revenue for the nine months ended September 30, 2010.   This amount was originally accrued in the NextRx opening balance sheet and, in accordance with business combination accounting guidance, the reversal of the accrual was recorded in revenue, since it
'/>"/>

SOURCE Express Scripts, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. ALS TDI Completes Gene Expression Profile of Lou Gehrigs Disease in Mice
2. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
3. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
4. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
5. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
6. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
7. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
8. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
9. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
10. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MILFORD, Pa. , Sept. 17, 2014  Fortune ... has officially changed its name to Manzo Pharmaceuticals, Inc. ... change to take effect today, September 17, 2014. Also ... split. The approval is a pivotal event ... Manzo . Mr. Manzo explained, "We could not proceed ...
(Date:9/17/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ... outstanding shares of Auxilium common stock at a price ... subject to due diligence, financing and other conditions. A ... from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... -- Mindray (NYSE: MR)announced its new generation DC-70 ultrasound ... been showcased for the first time at ISUOG in ... is scheduled for availability in the U.S. market in ... efficient workhorse in the mid-range segment, the DC-70 combines ... user experience including a gesture-sensitive touch screen, delivering accurate ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 ... http://www.marijuanastock.net , recently launched a “Video” section ... different cannabis companies in the marijuana industry made ... section, a website visitor is given access to ... relevant to marijuana-related businesses and the issues they ...
(Date:9/17/2014)... 17, 2014 NetDimensions (AIM: NETD; OTCQX: ... management systems, announces the opening of the 2014 Next ... , "We are very excited to meet up in ... interest in Next Steps from our clients and partners, ... really is. We look forward to some very engaging ...
(Date:9/17/2014)... 2014 Tina Griffin, a Senior Sales Associate ... chemotherapy but not her fight against cancer. Though weakened by ... Suncoast “Race for the Cure” on Saturday, Oct. 11, in ... Race for the Cure because I wanted to make an ... As part of her efforts, she is asking those who ...
(Date:9/17/2014)... Angeldress.co.uk is a popular online supplier; ... for worldwide clients. According to Leo, the company’s marketing ... first flagship retail store. Moreover, it is a market ... unveiled its new range of amazing wedding dresses and ... products are offered at greatly discounted prices, from 20% ...
(Date:9/17/2014)... September 17, 2014 In a new ... Dr. William Groff, an expert on the condition known as ... Pearly penile papules , or PPP, is a condition that ... other men may be affected as well. The condition is ... , “While PPP is not a sexually transmitted disease ...
Breaking Medicine News(10 mins):Health News:MarijuanaStock.net Adds Business News Video Section to Their Website 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3Health News:Tina Griffin’s Fight Against Cancer Didn’t Stop With her Chemotherapy—Her Next Step Is to Run in the Suncoast ‘Race for the Cure’ Oct. 11 2Health News:Angeldress.co.uk Is Planning To Open Its First Retail Store And Offering Big Savings On Amazing Wedding Dresses 2Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3
... low for people who suffer from traumatic brain injury ... function. TBI can impair a patient,s mental abilities, impact ... And long-term medical treatment carries a high economic cost. ... Air Force, Prof. Chaim Pick of Tel Aviv University,s ...
... , This release is available in German ... Foundation) is to establish 20 Collaborative Research Centres (CRCs) by ... Committee at its spring session in Bonn. The new CRCs ... percent programme allowance for indirect project costs) for the initial ...
... not won in a single battle: Long after a cancer has ... is under debate, and much is unclear. New research led by ... blood cancer, the source of cancer recurrence is in a set ... cells, and thus able to survive chemotherapy. The findings, which appeared ...
... TUESDAY, May 29 (HealthDay News) -- People with less than ... problems with their thinking skills later in life, according to ... researchers from Harvard University noted that people with more education ... thinking, or so-called "cognitive," skills, even if they had the ...
... Dotinga HealthDay Reporter , MONDAY, May 28 (HealthDay ... pounds because her friends sit around? A small study ... after-school programs if they hung out with active kids, and ... that friends directly affect how active kids are, and it,s ...
... treatment for suspected HIV is critical, pre-exposure preventive treatment ... people in high-risk groups, states a review of evidence ... "Although postexposure prophylaxis has a long history of ... treatment in the course of infection ("treatment as prevention") ...
Cached Medicine News:Health News:Diabetes drug could be a promising therapy for traumatic brain injury 2Health News:Diabetes drug could be a promising therapy for traumatic brain injury 3Health News:DFG establishes 20 new Collaborative Research Centres 2Health News:DFG establishes 20 new Collaborative Research Centres 3Health News:DFG establishes 20 new Collaborative Research Centres 4Health News:DFG establishes 20 new Collaborative Research Centres 5Health News:DFG establishes 20 new Collaborative Research Centres 6Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:Education May Protect Brain From Exposure to Solvents 2Health News:Key to More Active, Slimmer Kids: Friends 2Health News:Antiretroviral treatment for preventing HIV infection: an evidence review for physicians 2
... Gemini is the newest addition to Laserscopes ... distinct wavelengths to choose from, 1064nm Nd:YAG ... in an exploding non-invasive aesthetic laser market ... and effectiveness while maintaining the safety and ...
... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
... biolitecs Ceralas D 980 nm diode laser ... bloodless field for most surgical procedures. ... cuts optically without collateral tissue damage ... coagulates blood instantly and seals small blood ...
... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
Medicine Products: